Monday March 8, 8:38 pm Eastern Time
Company Press Release
Beckman Coulter and Immunomedics Announce
Funding of Their Joint Venture for Cancer
Therapeutics
FULLERTON, Calif.--(BW HealthWire)--March 8, 1999--Beckman Coulter, Inc.
(NYSE:BEC - news) and Immunomedics, Inc. (Nasdaq:IMMU - news) Monday
announced that their joint venture in cancer therapeutics, IBC Pharmaceuticals, L.L.C., has received start-up funding from a
private investor group. The group received a 7 percent interest in IBC based on a $35 million valuation.
Operations will begin at Immunomedics facilities in New Jersey and Beckman Coulter facilities in Marseilles, France.
Immunomedics' Chairman, Dr. David M. Goldenberg, will also serve as Chairman of IBC and Dr. Jacques Barbet, one of the
inventors of IBC's technology, will direct the European operations. Other IBC officers are Michael Brochu, CEO, formerly
Vice President of business development at Coulter Corporation and Richard Williams, CFO, also Chairman of Medco
Research and a Director of Immunomedics.
IBC was formed in 1998 when Beckman Coulter and a majority-owned subsidiary of Immunomedics each contributed basic
patents, with the intention of finding outside investors to fund further development. At that time, their ownership positions were
47 percent and 53 percent respectively.
The joint venture will attempt to develop new therapies that selectively irradiate cancer cells in a two-step process. Treatment
would begin with injection of a bispecific antibody that targets the cancer. These proprietary antibodies then bind with a
radiolabeled carrier that is injected later as a second step.
Immunomedics, through its subsidiary, has contributed its proprietary humanized antibody against the cancer marker
carcinoembryonic antigen, which is used in its CEA-Cide(a) therapeutic. Beckman Coulter has provided other antibodies and a
license to patents covering its bispecific targeting technology called the ''Affinity Enhancement System'' or AES. This method
can also be used to selectively deliver non-isotopic agents.
Beckman Coulter's Chairman, President and CEO, John P. Wareham, commented, ''This venture brings together key
technologies and shares development risk with outside investors. We are pleased to have found a way to further this promising
therapy.''
Dr. Goldenberg stated, ''Animal and clinical studies have shown that the IBC technology can deliver diagnostic and therapeutic
isotopes to cancer cells, especially in patients with small-cell lung or medullary thyroid cancers. We plan to extend our
capabilities to colorectal, breast, non-small cell lung and prostate cancers. These efforts are being pursued in tandem with
Immunomedics' trials of CEA-Cide(a) and LymphoCide(a) that use directly labeled anticancer antibodies.''
Dr. Barbet added, ''To-date, over 300 cancer patients have been studied using the IBC technology, and we have published
animal and clinical studies demonstrating improved targeting and encouraging therapeutic responses. The clinical studies have
been directed by Professor J.F. Chatal of Nantes, France, who is a prominent European investigator in nuclear medicine.''
Beckman Coulter, Inc. is a leading provider of instrument systems and complementary products that simplify and automate
processes in life science and clinical laboratories. The company's products are used throughout the world in all phases of the
battle against disease, from pioneering medical research and drug discovery to diagnostic testing that aids in patient treatment.
Annual sales for the company totaled $1.7 billion in 1998, with about half of this amount generated outside the United States.
Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic
imaging and thereapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products
are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic
agents to tumors and sites of infection. The Company's first product, CEA-SCAN(a) for the detection of colorectal cancer, is
being marketed in the United States and Europe (approved in Canada). The Company's second diagnostic imaging product,
LeukoScan(a), is being marketed in Europe for the diagnosis of osteomyelitis (bone infection). This product is presently under
regulatory review by the U.S. Food and Drug Administration. Immunomedics also has several other diagnostic imaging
products and two therapeutic products in clinical trials.
This press release contains forward-looking statements regarding the development and therapeutic value of the IBC technology.
While Beckman Coulter and Immunomedics believe that this is a promising area for research, this product is in the early phases
of development, and they can not offer any assurances that marketable products will be developed or, if they are developed,
that necessary government approvals can be obtained. The FDA has not approved this technology for therapeutic use. Only
limited clinical studies have been performed and additional studies may show that the technology has limited clinical utility, is not
sufficiently effective, or has side effects that render it unacceptable for therapeutic use.
(a) The CEA-Cide, the LymphoCide, the CEA-SCAN and LeukoScan are trademarks of Immunomedics Inc.
Contact:
Beckman Coulter, Fullerton
Jay Steffenhagen, 714/773-7620
or
Immunomedics, Morris Planes, New Jersey
Cynthia Sullivan, 973/605-8200 Ext 109 |
